Avoro Calls Merck's $180/sh Offer for Acceleron Pharma (XLRN) Inadequate; Urges Shareholders Not to Tender
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Avoro Capital Releases Presentation Detailing Why Acceleron Shareholders Should Not Tender Into Merck’s Inadequate Offer
November 9, 2021 5:31 PM ESTBelieves Now Is the Wrong Time to Cash out of Acceleron, Given Companys Strong Momentum and Near-Term Inflection Point Coming from Phase 3 Data
Sees Continuing as Standalone Entity as Clearly Superior Path for Acceleron
Highlights What It Believes Was a Flawed and Inadequate Sale Process, Including Not Pursuing Other Strategic Alternatives
Avoro Stands Ready to Support an Independent Acceleron
NEW YORK--(BUSINESS WIRE)-- Avoro Capital Advisors (Avoro), a long-term and collaborative investor in life sciences and biotechnology companies, together with certain of its... More
